Filgrastim post-chemotherapy mobilizes more CD34+ cells compared to its use during steady-state haemopoiesis.
Perez-Oteyza
J
J
Garcia-Laraña
J
J
Ramos
P
P
Zamora
C
C
Lopez-Jimenez
J
J
Roldan
E
E
Odriozola
J
J
D018952:Antigens, CD34 / Q000032:analysis*; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage* / Q000494:pharmacology; D006410:Hematopoiesis / Q000187:drug effects; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology
D018952:Antigens, CD34; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000069585:Filgrastim